Arbutus Biopharma ABUS 深 沪
已收盘 10-02 16:00:00 美东时间
4.45
-0.110
-2.41%
华盛通- 最 高4.68
- 今 开4.55
- 成交量 898.74万股
- 最 低 4.375
- 昨 收 4.56
- 总市值 8.82亿
- 52周最高 5.45
- 市盈率 静 --
- 换手率 4.54%
- 52周最低 3.50
- 委 比 -88.95%
- 总股本 1.98亿
- 历史最高 31.48
- 量 比 0.57
- 振 幅 6.69%
- 历史最低 0.821
- 每 手 1
- 风险率 0.29%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多期权扫描 | 加密市场爆发！Strategy多张CALL单狂飙逾800%；美光期权成交放量近100%
加密市场爆发！Strategy多张CALL单狂飙逾800%；瑞银唱多存储，美光期权成交放量近100%！近6成押注后市上涨>>
09-21 19:27
Why Is Arbutus Biopharma Stock Gaining Friday?
Arbutus Biopharma Corp. (NASDAQ:ABUS) stock traded higher Friday after the company announced plans to repurchase up to $230 million of its common stock through a modified Dutch auction tender offer. The clinical-stage biotech plans to offer shareholders between $5 and $5.75 per share in cash. Arbutu...
08-22 00:36
Arbutus Biopharma Plans To Commence Modified Dutch Auction Tender Offer To Repurchase Up To $230M Of Common Shares At Purchase Price Of Between $5.00 And $5.75 Per Share In Cash
Arbutus Biopharma Corporation (NASDAQ:ABUS) ("Arbutus" or the "Company"), a clinical-stage biopharmaceutical company focused on infectious disease, today announced plans to commence a modified "Dutch Auction" tender offer (the "Offer") to repurchase up to US$230 million of its common shares at a pur...
08-21 20:01
Arbutus Announces Intent to Repurchase Up to US$230 Million of its Common Shares Through Modified “Dutch Auction” Tender Offer
Arbutus Biopharma plans to launch a modified Dutch Auction tender offer to repurchase up to $230 million of its common shares at $5.00 to $5.75 per share, funded by cash on hand. The offer is expected to begin on August 24, 2026, and expire on September 29, 2026, subject to regulatory approvals. The company aims to return proceeds from its March 2026 settlement with Moderna to shareholders while continuing to enforce its intellectual property rig...
08-21 11:30
Arbutus Biopharma Q2 EPS $(0.03) Misses $(0.02) Estimate, Sales $1.014M Beat $700.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly losses of $(0.03) per share which missed the analyst consensus estimate of $(0.02) by 50 percent. This is a 400 percent decrease over earnings of $0.01 per share from the same period last year. The company reported quarterly sales of $1.014 million ...
08-12 19:34
Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update
Arbutus Biopharma reported Q2 2026 financial results with $92.6M in cash, cash equivalents, and marketable securities. The company received $178M from Moderna's settlement and expects to return up to $230M to shareholders. Arbutus filed three international patent enforcement lawsuits against Pfizer and BioNTech over lipid nanoparticle (LNP) technology. The FDA granted Fast Track designation for imdusiran to treat chronic hepatitis B and aligned o...
08-12 11:30
Arbutus Biopharma Announces Filing Of Three International Lawsuits Seeking To Enforce Patents Protecting LNP Technology Against Pfizer, BioNTech And Certain Of Their Affiliates
Arbutus and its exclusive licensee, Genevant, filed three international lawsuits seeking to enforce patents protecting their innovative lipid nanoparticle ("LNP") technology against Pfizer and BioNTech Received approximately $178M from Moderna as Arbutus’ share of the noncontingent payment under th...
07-16 19:39
Arbutus Initiates International Patent Infringement Enforcement Actions Against Pfizer and BioNTech, Receives First Payment From Moderna Settlement Agreement and Announces Intent to Return Capital to Shareholders
Arbutus Biopharma and its licensee, Genevant, filed international lawsuits against Pfizer and BioNTech to enforce their lipid nanoparticle (LNP) patents. Arbutus received $178M from Moderna as part of a settlement for patent infringement. The company expects a dividend from Genevant in Q3 2026 and plans to return up to $230M to shareholders through share repurchases.
07-16 11:30
Arbutus Biopharma Q1 EPS $0.87 Beats $(0.04) Estimate, Sales $179.126M Beat $750.000K Estimate
Arbutus Biopharma (NASDAQ:ABUS) reported quarterly earnings of $0.87 per share which beat the analyst consensus estimate of $(0.04) by 2275 percent. This is a 769.23 percent increase over losses of $(0.13) per share from
05-13 19:45
